Evogene Story

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:3em;'>EVG</div>
EVGN -- USA Stock  

USD 6.08  0.13  2.18%

The stock is still going through an active upward rally. While many of us are getting excited about healthcare space, we are going to outline the feasibility of picking up Evogene. We will analyze why Evogene investors may still consider a stake in the business given the latest economic outlook.
Published over three months ago
View all stories for Evogene | View All Stories
Our latest take on Evogene (NASDAQ:EVGN) analyst consensus
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Evogene has an asset utilization ratio of 0.52 percent. This suggests that the company is making $0.005204 for each dollar of assets. An increasing asset utilization means that Evogene is more efficient with each dollar of assets it utilizes for everyday operations.
What is the right price you would pay to acquire a share of Evogene? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our stock advisor page.

How important is Evogene's Liquidity

Evogene financial leverage refers to using borrowed capital as a funding source to finance Evogene ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Evogene financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Evogene's total debt and its cash.

How Evogene utilizes its cash?

To perform a cash flow analysis of Evogene, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Evogene is receiving and how much cash it distributes out in a given period. The Evogene cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Evogene Net Cash Flow from Operations is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (16.32 Million)

Is Evogene a risky opportunity?

Let's check the volatility. Evogene is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Evogene (NASDAQ:EVGN) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. picking up a share of an Evogene stock makes you a part-owner of that company.

Evogene Current Consensus

Here is the latest trade recommendation based on an ongoing consensus estimate among financial analysis covering Evogene. The Evogene consensus assessment is calculated by taking the average estimates from all of the analysts covering Evogene

Strong Buy
1
Hold
1
Strong Buy150.0
Buy00.0
Hold150.0
Sell00.0
Strong Sell00.0

Will Evogene growth be feasible after the rise?

The coefficient of variation is down to 494.55 as of today. Evogene is displaying above-average volatility over the selected time horizon. Investors should scrutinize Evogene independently to ensure intended market timing strategies are aligned with expectations about Evogene volatility.

Whereas some other companies under the biotechnology industry are still a bit expensive, Evogene may offer a potential longer-term growth to institutional investors. To conclude, as of the 19th of September 2020, we see that Evogene almost neglects market trends. The company is undervalued with very small probability of financial unrest within the next 24 months. However, our ongoing 30 days recommendation on the company is Strong Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Evogene. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com